This ADE is most likely the result of a drug-drug interaction (DDI) between ticagrelor and statins because ticagrelor is a CYP3A4 substrate and a weak inhibitor of CYP3A4, which may lead to increased concentrations of statins such as simvastatin, leading to rhabdomyolysis. The gene discussed is CYP3A4; the disease is rhabdomyolysis.